tential complications in the nursing infant include alterations of gut flora that might result in diarrhea or other related complications (e.g., dehydration). Cefotaxime is generally considered compatible for use for breast-feeding women by the American Academy of Pediatrics. Consider the benefits of breast-feeding, the risk of potential infant drug exposure, and the risk of an untreated or inadequately treated condition. If a breast-feeding infant experiences an adverse effect related to a maternally administered drug, healthcare providers are encouraged to report the adverse effect to the FDA.
Agranulocytosis, hematological disease, leukopenia, neutropenia, thrombocytopenia
Use cefotaxime with caution in patients with hematological disease. Hematological abnormalities, such as leukopenia, neutropenia, thrombocytopenia, granulocytopenia, and more rarely, bone marrow failure, pancytopenia, or agranulocytosis, may occur during treatment with cefotaxime. Monitor blood counts for courses of therapy lasting longer than 10 days. Treatment discontinuation should be considered in cases of abnormal results.
Sexually transmitted disease
While cefotaxime may be used to treat certain sexually transmitted diseases (STD), the drug may mask or delay the symptoms of incubating syphilis when given as part of an STD treatment regimen. All patients with a diagnosed or suspected STD should be tested for other STDs, which may include HIV, syphilis, chlamydia, and gonorrhea, at the time of diagnosis. Initiate appropriate therapy and perform follow-up testing as recommended based upon sexually transmitted disease diagnosis.
ADVERSE REACTIONS
Severe
hemolytic anemia / Delayed / 0-1.0
seizures / Delayed / 0-1.0
agranulocytosis / Delayed / Incidence not known
pancytopenia / Delayed / Incidence not known
aplastic anemia / Delayed / Incidence not known
anaphylactoid reactions / Rapid / Incidence not known
renal failure (unspecified) / Delayed / Incidence not known
toxic epidermal necrolysis / Delayed / Incidence not known
azotemia / Delayed / Incidence not known
interstitial nephritis / Delayed / Incidence not known
erythema multiforme / Delayed / Incidence not known
angioedema / Rapid / Incidence not known
Stevens-Johnson syndrome / Delayed / Incidence not known
cholecystitis / Delayed / Incidence not known
acute generalized exanthematous pustulosis (AGEP) / Delayed / Incidence not known
Moderate
eosinophilia / Delayed / 2.4-2.4
colitis / Delayed / 1.4-1.4
leukopenia / Delayed / 0-1.0
neutropenia / Delayed / 0-1.0
vaginitis / Delayed / 0-1.0
candidiasis / Delayed / 0-1.0
elevated hepatic enzymes / Delayed / 0-1.0
thrombocytopenia / Delayed / Incidence not known
bleeding / Early / Incidence not known
cholestasis / Delayed / Incidence not known
cholelithiasis / Delayed / Incidence not known
pseudomembranous colitis / Delayed / Incidence not known
Mild
injection site reaction / Rapid / 4.3-4.3
fever / Early / 2.4-2.4
pruritus / Rapid / 2.4-2.4
maculopapular rash / Early / 2.4-2.4
nausea / Early / 1.4-1.4
diarrhea / Early / 1.4-1.4
vomiting / Early / 1.4-1.4
headache / Early / 0-1.0
urticaria / Rapid / Incidence not known
dizziness / Early / Incidence not known
malaise / Early / Incidence not known
abdominal pain / Early / Incidence not known
DRUG INTERACTIONS
Amikacin: Cefotaxime's product label states that cephalosporins may potentiate the adverse renal effects of nep |
